Details of the presentation are as follows:
Abstract: 659
Title: Nemvaleukin alfa combination therapy for gastrointestinal (GI) cancers: preclinical evidence and clinical data from the ARTISTRY-1 trial
Presenter:
Presentation Date: The poster, along with a pre-recorded presentation, will be available on the ASCO GI virtual meeting platform beginning
About Nemvaleukin Alfa ('nemvaleukin')
Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to preferentially expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by selectively binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.
About the Nemvaleukin Clinical Development Program
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with advanced solid tumors.
About
KEYTRUDA is a registered trademark of
Contact:
Investors
T: +1 781 609 6377
Media
Sourojit Bhowmick, Ph.D.
T: +1 781 609 6397
(C) 2022 Electronic News Publishing, source